Bevacizumab, a monoclonal antibody against VEGFR, is beneficial in combination with chemotherapy for advanced NS‐NSCLC, and Bev‐chemotherapy has been the standard treatment for advanced NS‐NSCLC. The gene discussed is KDR; the disease is non-small cell lung carcinoma.